Update on rifampin, rifabutin, and rifapentine drug interactions

被引:129
作者
Baciewicz, Anne M. [1 ]
Chrisman, Cary R. [2 ]
Finch, Christopher K. [3 ]
Self, Timothy H. [3 ]
机构
[1] VA Puget Sound Hlth Care Ctr, Seattle, WA USA
[2] Methodist Med Ctr Oak Ridge, Oak Ridge, TN USA
[3] Univ Tennessee, Methodist Univ Hosp, Hlth Sci Ctr, Memphis, TN 38163 USA
关键词
Drug interactions; Rifabutin; Rifampin; Rifapentine; PLASMA-CONCENTRATIONS; TRANSPORTER INHIBITION; PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; ENZYME-INDUCTION; SINGLE-BLIND; PHARMACOKINETICS; ATORVASTATIN; CLOPIDOGREL; METABOLISM;
D O I
10.1185/03007995.2012.747952
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 64 条
[1]  
[Anonymous], 2011, BRIL TIC PROD INF
[2]  
[Anonymous], 2011, BRIL TIC UK SUMM PRO
[3]   RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (08) :1667-1671
[4]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH ;
BEKEMEYER, WB .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (03) :565-568
[5]   Update on rifampin and rifabutin drug interactions [J].
Baciewicz, Anne M. ;
Chrisman, Cary R. ;
Finch, Christopher K. ;
Self, Timothy H. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2008, 335 (02) :126-136
[6]   Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites [J].
Backman, JT ;
Lulurila, H ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :154-167
[7]   Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine [J].
Backman, JT ;
Granfors, MT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :451-461
[8]   Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome p450 inhibitors: A case report [J].
Bhaloo, S ;
Prasad, GVR .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) :2449-2451
[9]   The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].
Blech, Stefan ;
Ebner, Thomas ;
Ludwig-Schwellinger, Eva ;
Stangier, Joachim ;
Roth, Willy .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399
[10]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS .2. [J].
BORCHERDING, SM ;
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (04) :711-716